Welcome to our dedicated page for American Well SEC filings (Ticker: AMWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on American Well's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into American Well's regulatory disclosures and financial reporting.
American Well Corp received a Schedule 13G filing showing that investment entities associated with Jacob Ma-Weaver have accumulated a meaningful stake in the company. Funicular Funds, LP, Cable Car Capital, LP, and Jacob Ma‑Weaver each report beneficial ownership of 810,551 shares of Class A common stock, representing 5.5% of the class, based on 14,723,951 shares outstanding as disclosed in a prior Form 10‑Q. Each reporting person has sole voting and dispositive power over these shares and no shared power. They certify that the shares were not acquired to change or influence control of American Well, but instead are being reported on a passive basis.
American Well Corporation reported that it entered into an Amended and Restated Statement of Work with Elevance Health, Inc., effective January 1, 2026. This agreement extends their partnership under which American Well operates the white‑labelled LiveHealth Online® digital care delivery platform for Elevance Health. Elevance Health is obligated to pay American Well annual subscription fees and can separately engage the company for professional services, development, innovation, and engagement marketing work.
The new Statement of Work has a three‑year term, running from January 1, 2026 through January 1, 2029, and will automatically renew for additional one‑year periods unless either party terminates it. Either party may terminate for specified breaches or insolvency, and Elevance Health also has the right to terminate for certain security or confidentiality breaches, change‑of‑control events, or for convenience with 365 days’ advance written notice.
American Well Corp’s Chief Product & Technology Officer reported a routine tax-related stock sale. On 01/02/2026, the insider sold 6,243 shares of Class A common stock at $4.85 per share. According to the explanation, the sale was an automatic “sell to cover” transaction used to pay taxes arising from the vesting and settlement of restricted stock units on January 1, 2026, and did not represent a discretionary trade.
After this transaction, the reporting person beneficially owned 191,468 shares of American Well Corp stock, held directly.
American Well Corp officer reports small share sale for taxes. A company officer who serves as President, International reported selling 3,707 shares of American Well Class A common stock on 01/02/2026 at a price of $4.85 per share.
According to the filing, the sale was executed automatically to cover tax liabilities from restricted stock units that vested and settled on January 1, 2026, and did not represent a discretionary trade by the insider. After this transaction, the reporting person beneficially owns 119,870 shares directly and 114,250 shares indirectly through her husband.
American Well Corp’s Chief Accounting Officer reported a small insider sale of company stock. On 01/02/2026, the officer sold 384 shares of Class A common stock at a price of $4.85 per share, leaving a beneficial holding of 3,063 shares directly owned afterward. According to the disclosure, this sale was executed to cover tax liabilities from the vesting and settlement of restricted stock units on January 1, 2026, through an automatic “sell to cover” transaction rather than a discretionary trade.
American Well Corporation disclosed that it has extended its long-standing partnership with Elevance Health, Inc. for digital care services. On December 24 and 25, 2025, the company amended its Master Services Agreement and entered into a new Healthy Impact Statement of Work, effective January 1, 2026, to continue operating the white‑labelled LiveHealth Online® digital care platform. Under these agreements, Elevance Health pays annual subscription fees and can engage American Well for additional professional, development, innovation, and engagement marketing services.
Both the Master Services Agreement and the Healthy Impact Statement of Work now run for 3 years from January 1, 2026 through January 1, 2029, with automatic one‑year renewals unless terminated. Elevance Health has various termination rights, including for convenience with 365 days’ notice. American Well’s clinical partner, Online Care Group, PC, also extended related provider agreements for the same 3‑year term, ensuring continued prioritized access to a 50‑state network of clinicians who deliver digital care consultations to Elevance Health members via LiveHealth Online.
American Well Corporation reported a planned sale of restricted stock under Rule 144. The notice covers the proposed sale of 6,243 shares of Class A common stock through Morgan Stanley on the NYSE, with an aggregate market value of $30,284.79. The filing states that 14,723,951 shares of this class were outstanding and lists an approximate sale date of 01/02/2026.
The shares to be sold were acquired through the vesting of a restricted stock unit grant from American Well Corporation on 01/01/2026, when 11,831 shares vested and were treated as payment by vesting. The form also notes that the seller represents they are not aware of undisclosed material adverse information about the company’s current or prospective operations.
American Well Corporation insider Phyllis Gotlib has filed a notice of proposed sale of Class A Common Stock under Rule 144. The filing indicates an intent to sell 3,707 shares through broker Morgan Stanley on or about 01/02/2026, with an aggregate market value of $17,982.66, on the NYSE.
The shares to be sold come from a vesting event of restricted stock units. On 01/01/2026, 7,031 Class A shares were acquired through the vesting of a restricted stock unit grant from American Well Corporation, with payment also described as vesting of that grant. The filing also lists prior sales by Phyllis Gotlib over the past three months: 3,574 Class A shares sold on 12/01/2025 for gross proceeds of $14,501, and 4,959 Class A shares sold on 10/01/2025 for gross proceeds of $30,282.
American Well Corp director reports a small stock sale. A reporting person serving as a director of American Well Corp sold Class A Common Stock on 12/18/2025, in two market transactions: 600 shares at $4.71 per share and 12 shares at $4.75 per share, both held indirectly through her husband. After these sales, the indirect holdings through her husband were reduced to zero shares, while she continued to beneficially own 39,132 shares of Class A Common Stock directly.
American Well Corp reported an insider transaction by its President, International. On December 1, 2025, the reporting person sold 3,574 shares of Class A common stock at a price of $4.0573 per share. The filing explains that these sales were made solely to pay taxes arising from the vesting and settlement of restricted stock units on the same date through an automatic “sell to cover” transaction, rather than a discretionary trade.
After this transaction, the reporting person beneficially owns 123,577 Class A shares directly and 114,250 Class A shares indirectly through her husband. This reflects ongoing equity ownership in American Well while handling the tax impact of stock-based compensation.